Clinical trials
for patients
Learn about available clinical trials
-
October 13, 2025MadridIn recruitment
-
October 6, 2025Pamplona/MadridIn recruitment
1479-0012 Clinical trial to find an appropriate dose of zongertinib in combination with trastuzumab deruxtecan or trastuzumab emtansine, and to test whether it helps people with different types of HER2 cancer that has spread
The primary objective is to characterize the safety, tolerability and dose-toxicity curve of zongertinib in combination with T-DXd or in combination with T-DM1 in patients with HER2 metastatic breast cancer (mBC) or metastatic gastric or gastroesophageal adenocarcinoma (mGEAC) by evaluating escalating dose levels with overdose monitoring to achieve the primary objective of determining maximum tolerated doses (MTDs) and/or doses for future development. -
October 1, 2025Pamplona/MadridIn recruitmentEarly phase
CS45570 Clinical trial to evaluate the efficacy and safety of ro7790121 in patients with moderate to severe atopic dermatitis
The purpose of this trial is to test whether the experimental drug RO7790121 is safe and effective for moderate to severe atopic dermatitis and to find out what effects, good or bad, RO7790121 has versus placebo in atopic dermatitis -
October 1, 2025Pamplona/MadridIn recruitmentEarly phase
-
September 29, 2025Pamplona/MadridIn recruitment
NAPISTAR 1-01 Clinical trial to investigate the safety, tolerability, pharmacokinetics and efficacy of TUB-040 in patients with platinum-resistant large malignant ovarian cancer or non-small cell lung cancer.
The objective of this study is to evaluate a new drug (TUB-040) in two phases for patients with ovarian cancer or non-small cell lung cancer. -
September 24, 2025Pamplona/MadridIn recruitment
-
September 22, 2025PamplonaIn recruitmentEarly phase
D798VC00001 Clinical trial to evaluate the safety and efficacy of new interventions and study combinations in participants with colorectal cancer.
The objective of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also called MEDI5752), given in combination with a reference treatment for colorectal cancer. -
September 22, 2025Pamplona/MadridIn recruitment
SGNTUC-029 Phase III, open-label, randomized study of tucatinib in combination with trastuzumab and mFOLFOX6 vs. mFOLFOX6 given with or without cetuximab or bevacizumab as first-line treatment for patients with HER2 metastatic colorectal cancer.
The objective of this study is to test how tucatinib, trastuzumab and mFOLFOX6 perform for the treatment of HER2-positive colon or rectal cancer compared to mFOLFOX6 alone or mFOLFOX6 together with bevacizumab or cetuximab. -
September 15, 2025PamplonaIn recruitmentEarly phase
RIVER-81 Clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical efficacy of RVU120 in combination with venetoclax in participants with AML in whom previous treatment with venetoclax and a hypomethylating agent failed (RIVER-81).
The objectives of this study are to: ¿ Understand the appropriate dose of the study treatment (RVU120 venetoclax) for the subsequent study; ¿ Understand the effect of the study drug in reducing AML; ¿ Assess the tolerability of the study treatment and identify any potential side effects associated with the study drug; ¿ Perform pharmacokinetic (PK) testing to understand how the study treatment is metabolized and eliminated from the body; ¿ Assess how the study ... -
September 10, 2025PamplonaIn recruitmentEarly phase